Detalhe da pesquisa
1.
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
N Engl J Med
; 389(17): 1579-1589, 2023 Oct 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37888917
2.
Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry.
Pediatr Allergy Immunol
; 35(6): e14178, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38899688
3.
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
J Am Acad Dermatol
; 2024 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38653344
4.
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry.
Acta Derm Venereol
; 104: adv19454, 2024 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38323500
5.
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry.
Br J Dermatol
; 189(3): 327-335, 2023 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37177895
6.
A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis.
Br J Clin Pharmacol
; 89(1): 61-79, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36326810
7.
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
Acta Derm Venereol
; 103: adv00872, 2023 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36794894
8.
Unraveling heterogeneity in pediatric atopic dermatitis: Identification of serum biomarker based patient clusters.
J Allergy Clin Immunol
; 149(1): 125-134, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34237306
9.
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis.
Allergy
; 77(11): 3398-3407, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35837880
10.
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
Pediatr Allergy Immunol
; 33(12): e13887, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564878
11.
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry.
Acta Derm Venereol
; 102: adv00820, 2022 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36420885
12.
Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
Acta Derm Venereol
; 102: adv00712, 2022 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35356990
13.
The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry.
Contact Dermatitis
; 87(2): 185-191, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35279856
14.
Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers.
J Allergy Clin Immunol
; 147(1): 189-198, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32526312
15.
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
J Am Acad Dermatol
; 84(4): 1000-1009, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32946967
16.
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.
Acta Derm Venereol
; 101(11): adv00585, 2021 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34618162
17.
Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry.
Acta Derm Venereol
; 101(10): adv00573, 2021 Oct 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34396421
18.
Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
Allergy
; 75(1): 116-126, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31593343
19.
Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation.
Clin Exp Allergy
; 54(4): 294-296, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38158774
20.
Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies.
Clin Exp Allergy
; 53(5): 582-585, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36779570